Treatment options after first-line immunotherapy in metastatic NSCLC

References

• Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–957.
   PubMed Web of Science ®Google Scholar
• Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small cell lung cancer. N Engl J Med. 2010;363(18):1693–1703.
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Mok T, Kim DW, et al. PROFILE 1014 Investigators. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167–2177.
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123–132.
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–2139.
   PubMed Web of Science ®Google Scholar
• Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2(3):e73.
   Web of Science ®Google Scholar
• Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561–566.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371(21):1963–1971. Epub 2014 Sep 27.
   PubMed Web of Science ®Google Scholar
• Marchetti A, Felicioni L, Malatesta, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol. 2011;29(26):3574–3579.
   PubMed Web of Science ®Google Scholar
• Drilon A, Kummar S, Moreno V, et al. Activity of larotrectinib in TRK fusion lung cancer. Ann Oncol. 2019;30(Suppl2):111O. (abstr).
   Google Scholar
• Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378(8):731–739. PMID: 29466156.
   PubMed Web of Science ®Google Scholar
• Subbiah V, Gainor JF, Rahal R, et al. Precision targeted therapy with BLU-667 for RET-driven cancers. Cancer Discov. 2018;8(7):836–849.
   PubMed Web of Science ®Google Scholar
• Paik PK, Drilon A, Fan PD, et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov. 2015;5(8):842–849. PMID: 25971939.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–1639. PMID: 26412456.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–135. PMID: 26028407.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–1550.
   PubMed Web of Science ®Google Scholar
• Rittmeyer A, Barlesi F, Waterkamp D, et al. OAK study group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–265.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. KEYNOTE-024 investigators. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833. PMID: 27718847.
   PubMed Web of Science ®Google Scholar
• Mok TSK, Wu YL, Kudaba I, et al. KEYNOTE-042 Investigators. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819–1830. PMID: 30955977.
   PubMed Web of Science ®Google Scholar
• Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. KEYNOTE-189 investigators. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078–2092. PMID: 29658856.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Luft A, Vicente D, et al. KEYNOTE-407 investigators. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040–2051. PMID: 30280635.
   PubMed Web of Science ®Google Scholar
• Sharma P, Hu-Lieskovan S, Wargo JA, et al. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707–723. PMID: 28187290.
   PubMed Web of Science ®Google Scholar
• Crinò L, Mosconi AM, Scagliotti G, et al. Gemcitabine as second-line treatment for advanced non-small-cell lung cancer. A phase II trial. J Clin Oncol. 1999;17(7):2081–2085. PMID: 10561261.
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Crinò L. Gemcitabine in non-small cell lung cancer. Expert Opin Pharmacother. 2002;3(6):745–753. PMID: 12036414.
   PubMedGoogle Scholar
• Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 non-small cell lung cancer study group. J Clin Oncol. 2000;18(12):2354–2362. PMID: 10856094.
   PubMed Web of Science ®Google Scholar
• Dancey J, Shepherd FA, Gralla RJ, et al. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial. Lung Cancer. 2004;43(2):183–194. PMID: 14739039.
   PubMed Web of Science ®Google Scholar
• Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384(9944):665–673. PMID: 24933332.
   PubMed Web of Science ®Google Scholar
• Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22(9):1589–1597. PMID: 15117980.
   PubMed Web of Science ®Google Scholar
• Soria JC, Felip E, Cobo M, et al. LUX-Lung 8 Investigators. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2015;16(8):897–907. PMID: 26156651.
   PubMed Web of Science ®Google Scholar
• Reck M, Kaiser R, Mellemgaard A, et al. LUME-lung 1 study group. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014;15(2):143–155. PMID: 24411639.
   PubMed Web of Science ®Google Scholar
• Santos ES, Gomez JE, Raez LE. Targeting angiogenesis from multiple pathways simultaneously: BIBF 1120, an investigational novel triple angiokinase inhibitor. Invest New Drugs. 2011;30(3):1261–1269. PMID: 21350804.
   PubMed Web of Science ®Google Scholar
• Rolfo C, Raez L, Bronte G, et al. BIBF 1120/nintedanib: a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer. Expert Opin Investig Drugs. 2013;22:1081–1088.
   PubMed Web of Science ®Google Scholar
• Hilberg F, Roth G, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008;68:4774–4782.
   PubMed Web of Science ®Google Scholar
• Vargatef. [cited 2019 Oct 31]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/vargatef
   Google Scholar
• Christian Groh´e C, Gleiber W, Haas S, et al. Nintedanib plus docetaxel after progression on immune checkpoint inhibitor therapy: insights from VARGADO, a prospective study in patients with lung adenocarcinoma. Future Oncol. 15(23): 2699–2706. 2019.
   PubMed Web of Science ®Google Scholar
• Leal TA, Spira AI, Blakely C, et al. Stage 2 enrollment complete: sitravatinib in combination with nivolumab in NSCLC patients progressing on prior checkpoint inhibitor therapy. Ann Oncol. 2018;29(suppl8):viii400–viii441.
   PubMedGoogle Scholar
• Phase 3 study of sitravatinib plus nivolumab vs docetaxel in patients with advanced non-squamous NSCLC. [cited 2019 Nov 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT03906071
   Google Scholar
• Makker V, Rasco D, Vogelzang NJ, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;20(5):711–718.
   PubMed Web of Science ®Google Scholar
• Tohyama O, Matsui J, Kodama K, et al. Antitumor activity of lenvatinib (E7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res. 2014;2014:638747.
   PubMedGoogle Scholar
• Voron T, Colussi O, Marcheteau E, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med. 2015;212:139‐148.
   PubMed Web of Science ®Google Scholar
• Courau T, Nehar-Belaid D, Florez L, et al. TGF-beta and VEGF cooperatively control the immunotolerant tumor environment and the efficacy of cancer immunotherapies. JCI Insight. 2016;1:e85974.
   PubMed Web of Science ®Google Scholar
• Hato T, Zhu AX, Duda DG. Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma. Immunotherapy. 2016;8:299‐313.
   PubMed Web of Science ®Google Scholar
• Kimura T, Kato Y, Ozawa Y, et al. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model. Cancer Sci. 2018;109:3993–4002.
   PubMed Web of Science ®Google Scholar
• Efficacy and safety of pembrolizumab (MK-3475) with lenvatinib (E7080/MK-7902) vs. Docetaxel in participants with metastatic non-small cell lung cancer (NSCLC) and progressive disease (PD) after platinum doublet chemotherapy and immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008). [cited 2019 Nov 13]. Available from: https://clinicaltrials.gov/ct2/show/NCT03976375
   Google Scholar
• Okuma HS, Yonemori K. BRCA gene mutations and poly (ADP-Ribose) polymerase inhibitors in triple-negative breast cancer. In: Song E, Hu H, editors. translational research in breast cancer: biomarker diagnosis; targeted therapies and approaches to precision medicine. Singapore: Springer Singapore; 2017. p. 271–286.
   Google Scholar
• Broustas CG, Lieberman HB. DNA damage response genes and the development of cancer metastasis. Radiat Res. 2014;181:111–130.
   PubMed Web of Science ®Google Scholar
• Jiao S, Xia W, Yamaguchi H, et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res. 2017;23:3711–3720.
   PubMed Web of Science ®Google Scholar
• Hu-Lieskovan S, Ribas A. New combination strategies using programmed cell death 1/programmed cell death ligand 1 checkpoint inhibitors as a backbone. Cancer J. 2017;23:10–22.
   PubMed Web of Science ®Google Scholar
• Study of pembrolizumab with maintenance olaparib or maintenance pemetrexed in first line (1L) metastatic nonsquamous non-small-cell lung cancer (NSCLC) (MK-7339-006, KEYLYNK-006). [cited 2019 Nov 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT03976323
   Google Scholar
• Charych D, Khalili S, Dixit V, et al. Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy. PLoS One. 2017;12:e0179431.
   PubMed Web of Science ®Google Scholar
• Hoch U, Langowski JL, Lee SR, et al. NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models. Clin Cancer Res. 2016;22:680–690.
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568–571.
   PubMed Web of Science ®Google Scholar
• Daud AI, Loo K, Pauli ML, et al. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J Clin Invest. 2016;126:3447–3452.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014;192:5451–5458.
   PubMed Web of Science ®Google Scholar
• Bernatchez C, Haymaker CL, Hurwitz ME, et al. Effect of a novel IL-2 cytokine immune agonist (NKTR-214) on proliferating CD8+T cells and PD-1 expression on immune cells in the tumor microenvironment in patients with prior checkpoint therapy. 2017 ASCO Annual meeting, abstract 2545. DOI:10.1200/JCO.2017.35.15_suppl.2545
   Google Scholar
• A phase 1/2 multicenter dose escalation and expansion study of NKTR-214 in subjects with locally advanced or metastatic solid tumors (NKTR-214). [cited 2019 Nov 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT02869295
   Google Scholar
• A dose escalation and cohort expansion study of NKTR-214 in combination with nivolumab and other anti-cancer therapies in patients with select advanced solid tumors (PIVOT-02). [cited 2019 Nov 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT02983045
   Google Scholar
• A study of a CD122-biased cytokine (NKTR-214) in combination with anti-PD-1 (Pembrolizumab) in patients with select advanced or metastatic solid tumors (PROPEL). [cited 2019 Nov 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT03138889
   Google Scholar
• A study of NKTR-214 in combination with nivolumab in patients with metastatic and/or locally advanced sarcoma. [cited 2019 Nov 13]. Available from: https://clinicaltrials.gov/ct2/show/NCT03282344
   Google Scholar
• Kato S, Goodman A, Walavalkar V, et al. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res. 2017;23(15):4242–4250.
   PubMed Web of Science ®Google Scholar
• Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(6371):91–97.
   PubMed Web of Science ®Google Scholar
• Skoulidis F, Goldberg ME, Greenawalt DM, et al. STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov. 2018;8:822–835.
   PubMed Web of Science ®Google Scholar
• Pu X, Wu L, Su D, et al. Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance. BMC Cancer. 2018;18:1082.
   PubMed Web of Science ®Google Scholar
• Yan X, Wang L, Zhang R, et al. Overcoming resistance to anti-PD immunotherapy in a syngeneic mouse lung cancer model using locoregional virotherapy. Oncoimmunol. 2018;7(1):e1376156.
   Web of Science ®Google Scholar
• Ribas A, Dummer R, Puzanov I, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170(6):1109–1119.e1110.
   PubMed Web of Science ®Google Scholar
• Vergnenegre A, Monnet I, Bizieux A, et al. Open-label phase II trial to evaluate safety and efficacy of second-line metronomic oral vinorelbine–atezolizumab combination for stage-IV non-small-cell lung cancer – vinMetAtezo trial, (GFPC‡ 04-2017). Future Oncol. 2020;16(4):5–10.
   PubMedGoogle Scholar